Pages that link to "Q41085746"
Jump to navigation
Jump to search
The following pages link to Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results (Q41085746):
Displaying 50 items.
- Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review (Q24678961) (← links)
- Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer (Q24799908) (← links)
- Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study (Q28364203) (← links)
- miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers (Q28728333) (← links)
- Recent developments in weekly paclitaxel therapy in lung cancer (Q30652506) (← links)
- Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer. (Q30663239) (← links)
- Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma (Q31791219) (← links)
- Phase I study of paclitaxel (Taxol) plus vinorelbine (Navelbine) in patients with untreated stage IIIb and IV non-small cell lung cancer (Q31878724) (← links)
- Combination of paclitaxel and etoposide in the treatment of advanced non-small cell lung cancer: a phase I-II study (Q32100779) (← links)
- Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer (Q33329874) (← links)
- Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer (Q33330920) (← links)
- Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study (Q33331466) (← links)
- Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV). (Q33335588) (← links)
- Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer (Q33339502) (← links)
- Phase II study of paclitaxel (Genaxol) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC). (Q33344579) (← links)
- PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s (Q33418542) (← links)
- Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. (Q33488355) (← links)
- Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer (Q33499809) (← links)
- Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer (Q33502576) (← links)
- Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer? (Q33539673) (← links)
- Future directions with taxane therapy (Q33541925) (← links)
- Chemotherapy for Stage IV Non-Small Cell Lung Cancer: Protocol Versus Nonprotocol? Is Noninvestigational Treatment Worthwhile? Patient Selection? Which Regimen? What's Next? (Q33862696) (← links)
- Innovative treatment strategies in locally advanced and/or unresectable non-small cell lung cancer (Q33877442) (← links)
- Chemotherapy in non-small cell lung cancer (Q33945462) (← links)
- The role of new agents in advanced non-small-cell lung carcinoma (Q34107800) (← links)
- Taxanes in lung cancer: a review with focus on the European experience (Q34224849) (← links)
- The taxoids. Comparative clinical pharmacology and therapeutic potential (Q34456149) (← links)
- Therapy for stage IIIB and stage IV non-small cell lung cancer (Q34569395) (← links)
- Taxanes for advanced non-small cell lung cancer (Q35020524) (← links)
- Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer (Q35035781) (← links)
- A Novel Bioluminescence Orthotopic Mouse Model for Advanced Lung Cancer (Q35420117) (← links)
- Cardiotoxicities of paclitaxel in African Americans. (Q35585385) (← links)
- Basic treatment considerations: chemotherapy. (Q35684081) (← links)
- Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development (Q36074388) (← links)
- Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer (Q36075265) (← links)
- Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro (Q36421995) (← links)
- Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer (Q36612612) (← links)
- Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer (Q36617642) (← links)
- New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer (Q36680500) (← links)
- Emerging drug treatments for solid tumours (Q36811466) (← links)
- Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II. (Q37544369) (← links)
- Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage (Q38335859) (← links)
- miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression (Q38795063) (← links)
- A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. (Q39136326) (← links)
- In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin). (Q39428478) (← links)
- Rgulatable Transgene Expression for Prevention of Chemotherapy-Induced Peripheral Neuropathy (Q40076972) (← links)
- Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens (Q40109849) (← links)
- Regulatable Transgene Expression for Prevention of Chemotherapy-Induced Peripheral Neuropathy (Q40124861) (← links)
- Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer (Q40397088) (← links)
- Future directions in non-small cell lung cancer. A personal view. (Q40408807) (← links)